TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05464745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets
Description: Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets
Description: Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
Study: NCT05030727

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: record of pNGAL
Description: Preoperative (0.hour baseline), postoperative 24.,48. BUN, Creatinine, Lactate values in the blood of the patients at 1 hour, and for plasma NGAL, blood samples will be taken at the preoperative, postoperative 6th and 24th hours. And the results will be recorded.
Study: NCT05892887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Bilateral ultrasound guided in erector spinae plane block by bupivacaine 0.25%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Bilateral ultrasound guided in erector spinae plane block by bupivacaine 0.25%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Bilateral ultrasound guided in erector spinae plane block by bupivacaine 0.25%
Study: NCT05895526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self etch dentin adhesive, Fluoride varnish
Description: After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self etch dentin adhesive, Fluoride varnish
Description: After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.
Study: NCT05506280

Intervention type: PROCEDURE
Intervention: blood prolactin levels
Description: The extraction technique was performed by venipuncture in 110 veins located in the antecubital area with a 21G butterfly nut with a Vacutainer Safety 111 Lok@ adapter, a 2.5x45cm latex venous compressor and a tube with separating gel 112 (yellow cap)
Study: NCT05132803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPV 16 TA-CIN
Description: No dose escalation or reduction
Study: NCT05330910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm
Description: Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy arm
Description: Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
Study: NCT05504876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Syrup
Description: Administered Midazolam Syrup 5 mg orally once daily in fed state;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA
Description: Administered HEC74647PA 100 mg orally once daily in fed state;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114
Description: Administered HEC110114 600 mg orally once daily in fed state;
Study: NCT04655196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOLUS-D + weekly feedback by a coach
Description: internet-based self-help

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOLUS-D + weekly automated messages
Description: internet-based self-help
Study: NCT05391178

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumiton yarn sleeve
Description: Sleeve made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumiton yarn hat
Description: Hat made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumiton yarn shirt
Description: Shirt made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
Study: NCT04868552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-hospital naloxone education
Description: a 5-10 minute pre-hospital education module teaching patients and support persons how and when to administer naloxone
Study: NCT05980884

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days.
Study: NCT05559567

Intervention type: DEVICE
Group type: OTHER
Intervention: Orthokeratology
Description: The use of a specialty GP contact lens to temporarily correct myopia
Study: NCT04414735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: Infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence of a photosensitizer. The cellular product is obtained through leucopheresis and its subsequent exposure to 8-methoxypsoralen (8-MOP) and irradiation with UV-A light.
Study: NCT06247189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICOPE Monitoring
Description: At inclusion set up of the ICOPE monitor program on the patient's device and evaluation (all steps) of ICOPE Monitor program.~Monthly, re-evaluation of the patient (Step 1 and others if necessary ) according to the ICOPE Monitor program
Study: NCT06391632

Intervention type: DIAGNOSTIC_TEST
Intervention: Revised Cardiac Risk Index
Description: The Revised Cardiac Risk Index (RCRI) attempts to estimate the likelihood of cardiac complications during hospitalization in patients undergoing noncardiac surgery.The Frailty Index is a commonly used tool in clinical practice to assess the degree of frailty in patients.The Quality of Recovery-15 scale (QoR-15) is an easy-to-use score for assessing the quality of post-operative recovery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Revised Cardiac Risk Index
Description: The Revised Cardiac Risk Index (RCRI) attempts to estimate the likelihood of cardiac complications during hospitalization in patients undergoing noncardiac surgery.The Frailty Index is a commonly used tool in clinical practice to assess the degree of frailty in patients.The Quality of Recovery-15 scale (QoR-15) is an easy-to-use score for assessing the quality of post-operative recovery.
Study: NCT04925648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Dasatinib 100mg once daily orally for 14 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Dasatinib 100mg once daily orally for 14 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide
Description: Darolumatide 600 mg twice daily orally for 14 Days
Study: NCT05776563

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition visits
Description: Participants will receive exercise and dietary counseling from a nutritionist and registered dietician with extensive experience with diabetes and obesity every 2 weeks during the 12 wee

Intervention type: OTHER
Group type: OTHER
Intervention: Intensification of diabetes regimen
Description: Patient will meet every 2 weeks in person or have regular phone calls with an endocrinologist to review glucose control and intensification of the diabetes regimens. Will follow the general strategies outlined in the Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous glucose monitor (CGM)
Description: Individuals with uncontrolled T2DM will be asked use a CGM during the 12 week intervention, to monitor glucose control. Target blood glucose levels will be between 80-130 mg/dl before meals and \< 180 mg/dl at bedtime. Individuals not at goal with glycemic targets will undergo intensification of their regimen. Throughout the study, individuals will be contacted via telephone, email or through additional clinic visits as deemed necessary for maintenance of glycemic control.
Study: NCT06422234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Video-based game exercises will be performed 3 days a week for 6 weeks. Participants will be taught how to play the games before starting the game called Ring Fit Adventure, one of the Nintendo Switch games. Among the games within Ring Fit, games that aim to increase lower extremity muscle strength, core stabilization and balance have been selected, and game types and number of repetitions are changed every week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Game-free Exercise
Description: All activities in the exergame group were done without games and screens. The progression of the exercises proceeds in the same way as the other group.
Study: NCT05122702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified Shenling Baizhu San
Description: modified Shenling Baizhu San granules, twice daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules, twice daily for 12 weeks.
Study: NCT04685239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dual mobility cup
Description: The use of a Sunfit dual mobility cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: unipolar cup
Description: The use of a TMT cup
Study: NCT04978519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy is administered by using perineal needles, placed under ultrasound guidance to freeze the target tissue.
Study: NCT04226170

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DAS-001
Description: ondansetron + pyridostigmine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAS-001
Description: ondansetron + pyridostigmine
Study: NCT04457622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory perception tasks in healthy participants
Description: The participants complete auditory perception tasks while EEG, and MEG record brain signals (primary outcome measure). The tasks acquire behavioral responses with button presses (secondary outcome measure).~All analyses are intra-subject (no analyses are between-subject).
Study: NCT05908006

Intervention type: DEVICE
Intervention: Velacur
Description: Imaging Procedures Comparison
Study: NCT05451485

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood speckle tracking
Description: Blood speckle tracking measurements will be acquired of the carotid artery and superficial femoral artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood speckle tracking
Description: Blood speckle tracking measurements will be acquired of the carotid artery and superficial femoral artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound particle Imaging Velocimetry
Description: Ultrasound particle imaging velocimetry will be acquired of the carotid artery and superficial femoral artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound particle Imaging Velocimetry
Description: Ultrasound particle imaging velocimetry will be acquired of the carotid artery and superficial femoral artery

Intervention type: DIAGNOSTIC_TEST
Intervention: 4D flow MRI
Description: 4D flow MRI will be acquired of the carotid artery and superficial femoral artery

Intervention type: DIAGNOSTIC_TEST
Intervention: 4D flow MRI
Description: 4D flow MRI will be acquired of the carotid artery and superficial femoral artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional duplex
Description: Conventional duplex measurements will be acquired of the carotid artery and superficial femoral artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional duplex
Description: Conventional duplex measurements will be acquired of the carotid artery and superficial femoral artery
Study: NCT04734197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)
Description: combination of a topical immunosuppressant and a topical corticosteroid solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid 0.1%
Description: topical immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid 0.3%
Description: topical immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Sodium Phosphate 0.01%
Description: topical corticosteroid solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Vehicle
Description: topical vehicle solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine 0.05% Ophthalmic Emulsion
Description: topical ophthalmic emulsion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: topical ophthalmic solution
Study: NCT05845697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trigger point dry needling
Description: Filiform needle that pierces the skin and is inserted into an identified trigger point in the muscle

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling
Description: A validated sham dry needle that is blunted on the end and does not pierce the skin
Study: NCT05378009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation and physical activity
Description: This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
Study: NCT06427551

Intervention type: DRUG
Intervention: Ropivacaine
Description: The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)

Intervention type: DRUG
Intervention: Ropivacaine
Description: The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)

Intervention type: DRUG
Intervention: Ropivacaine
Description: The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)
Study: NCT05642650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel wearable device
Description: Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps after discharge.
Study: NCT05282056

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD analysis
Description: CAD shows the radiologist automatically delineated areas of potential COVID-19 affection, together with an overall lung affection percentage.
Study: NCT05680116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device
Description: Patients will wear Myovolt shoulder device twice a week and each session will continue 30minutes. This therapy will apply during the radiotherapy process. The device will be applied on the bare skin of the shoulder area. The first 10 minutes of the 30 minutes will be intermittent vibration, the other 20 minutes will be done in the sinusoidal vibration program. Both programs will be in the range of 20-100 Hz.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise
Description: Patients will do home based exercise during the radiotherapy process. 5 days a week. 2 sessions a day, each exercise will be 10x2 repetitions
Study: NCT04631094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group holding the serrated ball in the hand on the extremity from which venous blood will be taken
Description: Children in the experimental groups will squeeze the serrated ball during the blood draw.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.
Description: Children in the experimental groups will squeeze the serrated ball during the blood draw.
Study: NCT05861505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)
Description: Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeat local treatment
Description: Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeat local treatment
Description: Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection).
Study: NCT05650034

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Elective nodal de-escalation arm
Description: Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H\&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H\&N SCCs ( pN0 or by PETCT).
Study: NCT05459532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir 200 mg
Description: The drug is orally bioavailable (and is indicated for treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. The recommended dose is 800 mg (four 200 mg capsules) taken orally 12-hourly for five days, and should be administered as soon as possible after diagnosis of COVID-19 has been made and within five days of symptom onset.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Molnupiravir 200 mg
Description: The drug is orally bioavailable (and is indicated for treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. The recommended dose is 800 mg (four 200 mg capsules) taken orally 12-hourly for five days, and should be administered as soon as possible after diagnosis of COVID-19 has been made and within five days of symptom onset.
Study: NCT06183008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: Each patient will during the 30-week trial period get 3 IVIG courses (each total dose 2g/kg) for three consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient will during the 30-week trial period get 3 placebo courses (each 0.9% saline similar volume) for three consecutive days
Study: NCT04631094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group holding a smooth ball in the hand on the extremity from which venous blood will be taken
Description: Children in the experimental groups will squeeze the smooth ball during the blood draw.
Study: NCT05182047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butamirate citrate
Description: Butamirate citrate syrup will be administered orally.
Study: NCT04631094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.
Description: Children in the experimental groups will squeeze the smooth ball during the blood draw.
Study: NCT05053932

Intervention type: OTHER
Intervention: blood collection
Description: blood collection
Study: NCT05510271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Noise
Description: Orhan OSMAN's song Don't Let Your Baby Cry-2 from the Kolik album was used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yakson Touch
Description: In order to transfer the Ki energy to the baby, he took a deep breath and gathered the universal energy in his palms, intending the baby's well-being and healing. The researcher applied the Yakson touch by covering the abdomen and chest of the newborn with his right hand (dominant hand) while the newborn was in the supine position, and supported the baby's back and hips with his left hand.
Study: NCT05641389

Intervention type: OTHER
Intervention: Monitoring
Description: Participants will be monitored for alcohol use.
Study: NCT05182047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butamirate citrate
Description: Butamirate citrate syrup will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinecod
Description: Sinecod syrup will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinecod
Description: Sinecod syrup will be administered orally.